US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
aTyr Pharma Inc (ATYR)
aTyr Pharma Inc (ATYR) ニュース

ATYR

aTyr Pharma (ATYR)

aTyr Pharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ATYR

1

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/24	06 : 48	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ATYR	aTyr Pharma Inc
2024/12/24	06 : 42	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATYR	aTyr Pharma Inc
2024/12/17	22 : 00	GlobeNewswire Inc.	aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:ATYR	aTyr Pharma Inc
2024/12/13	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATYR	aTyr Pharma Inc
2024/12/13	06 : 12	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ATYR	aTyr Pharma Inc
2024/12/13	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATYR	aTyr Pharma Inc
2024/12/13	06 : 00	GlobeNewswire Inc.	aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors	NASDAQ:ATYR	aTyr Pharma Inc
2024/12/10	22 : 00	GlobeNewswire Inc.	aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis	NASDAQ:ATYR	aTyr Pharma Inc
2024/12/09	22 : 00	GlobeNewswire Inc.	aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis	NASDAQ:ATYR	aTyr Pharma Inc
2024/11/15	22 : 00	GlobeNewswire Inc.	aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis	NASDAQ:ATYR	aTyr Pharma Inc
2024/11/15	08 : 51	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ATYR	aTyr Pharma Inc
2024/11/08	06 : 07	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ATYR	aTyr Pharma Inc
2024/11/08	06 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATYR	aTyr Pharma Inc
2024/11/08	06 : 01	GlobeNewswire Inc.	aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update	NASDAQ:ATYR	aTyr Pharma Inc
2024/10/31	21 : 00	GlobeNewswire Inc.	aTyr Pharma to Present at Upcoming Investor Conferences	NASDAQ:ATYR	aTyr Pharma Inc
2024/10/16	06 : 01	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:ATYR	aTyr Pharma Inc
2024/10/08	21 : 00	GlobeNewswire Inc.	aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting	NASDAQ:ATYR	aTyr Pharma Inc
2024/10/02	21 : 00	GlobeNewswire Inc.	aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal	NASDAQ:ATYR	aTyr Pharma Inc
2024/08/21	21 : 00	GlobeNewswire Inc.	aTyr Pharma to Participate in September Investor Conferences	NASDAQ:ATYR	aTyr Pharma Inc
2024/08/14	05 : 00	GlobeNewswire Inc.	aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update	NASDAQ:ATYR	aTyr Pharma Inc
2024/08/06	21 : 00	GlobeNewswire Inc.	aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations	NASDAQ:ATYR	aTyr Pharma Inc
2024/07/30	21 : 00	GlobeNewswire Inc.	aTyr Pharma Announces Research Study with Stanford Medicine	NASDAQ:ATYR	aTyr Pharma Inc
2024/07/22	21 : 00	GlobeNewswire Inc.	aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis	NASDAQ:ATYR	aTyr Pharma Inc
2024/06/03	21 : 00	GlobeNewswire Inc.	aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”	NASDAQ:ATYR	aTyr Pharma Inc

Showing the most relevant articles for your search:NASDAQ:ATYR

1

US Dollar vs Yen

Financial Select Sector

BNP Paribas (QX)

US Dollar vs Euro

Deutsche Telekom (QX)

US Dollar vs Sterling

American Express

Gold vs US Dollar

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約